에 대한 최신 뉴스 Abbott Laboratories (NYSE:ABT) 주식

ABBOTT LABORATORIES

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Oct,15,,2019,Sunnyvale, - ,Ca, - ,Usa,-,Close

Analyst Color

Large Cap

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

수요일(22일) 애보트 래버러토리스(NYSE:ABT)는 4분기 매출이 전년 동기 대비 7.2% 증가한 109억 7,000만 달러로 컨센서스인 110억 1,000만 달러에 미치지 못했다고 발표했다.

애보트 래버러토리스, 목요일 주가 5% 가까이 오른 이유는?

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

Pre-Market Outlook

Markets

NFLX

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 추가적으로 개선되었음을 보여주었지만, 수요일(22일) 여전히 &#34;공포&#34; 영역에 머물렀다.미국 주식은 수요일에 상승 마감하였으며, S&amp;P 500 지수는 장중에 사상 최고가로 상승했다.

S&amp;P 500 사상 최고치 경신, 넷플릭스의 강력한 실적: 투자 심리 개선되었지만 탐욕 지수는 계속 &#39;공포&#39; 영역에

Tallinn,,Estonia,-,August,4th,2023,-,Computer,Display,With

Asia

Equities

Government

Regulations

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

AMZN

MAGS

MSFT

NVDA

ORCL

SCHW

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

S&amp;P 500이 수요일에 6,100포인트를 잠시 넘기며 새로운 사상 최고치를 기록했다. 이는 강력한 기업 실적과 도널드 트럼프 대통령의 5,000억 달러 규모의 인공지능(AI) 투자 계획인 &#34;AI 스타게이트&#34;의 발표로 월가가 긍정적으로 반응한 결과이다.

S&amp;P 500이 6,100의 최고가를 경신: 강력한 기업 실적, 트럼프의 AI 베팅이 상승을 격려

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Biotech

Abbott Laboratories Highlights Late-Breaking Data Of TriClip For People With Leaky Tricuspid Heart Valve

No one stumbles upon <a href="https://www.benzinga.com/personal-finance/24/12/42301100/most-americans-dont-see-wealth-as-the-key-to-financial-success-heres-what-matters-more-to-59-of-them">financial success</a> by accident. Wealth is built through discipline, learning from mistakes, and sticking to an approach even when the market seems to go awry. Few investing strategies showcase this better than <a href="https://www.benzinga.com/personal-finance/25/03/44374276/reddit-explodes-over-dividend-math-how-much-would-the-annual-dividend-be-for-a-280k-investment-investors-debate-schds-future-growth">dividend</a> investing.
Dividend investing is the slow-and-steady journey of the financial world, paying consistently while also providing growth in the background, making it perfect for retirees, long-term investors, and anyone who wants passive income.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Still, this approach can also be risky for some if they pick the wrong stocks. One military veteran and Reddit user recently shared his investing journey that started with him making costly mistakes to now earning him $10,000 in dividends per year.
With 13 years of investing experience, the poster, an enlisted service member, had to learn what works through trial and error. He says he tried to be smarter than the market early on, leading to him selling big winners too soon and holding onto losers for too long.
&#8220;I bought [General Electric] in my Roth at what I thought was a great price point of $14.50 or something. Had to [dollar-cost average] over several years to bring the cost basis down and missed out on having that money in better spots in the biggest bull market year I have been a part of,&#8221; he shared.
The 36-year-old mentioned that he&#8217;s gradually shifted his strategy to dividend shares now and his $296,570 portfolio already generates over $10,000 annually in dividends. Let&#8217;s see what dividend shares and ETFs the investor holds.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">From Fatal Mistakes to $10,000/Year in Dividend Income—Reddit Investor Shares Top 10 Stocks and ETFs in His Portfolio</h2>
Abbott Laboratories
Healthcare company, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) specializes in medical devices, pharmaceuticals, and nutritional products. With a 1.89% dividend yield per year, ABT is known for its diversified product portfolio and steady payments.
AbbVie
Pharmaceutical giant AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) focuses on the research and development of therapies for various health conditions. Investors love ABBV because it has a strong yield, generating around 3.28% in dividends per year, and a stable pipeline of drugs.
ConocoPhillips
Energy giant ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) engages in the exploration and production of oil and natural gas. COP pays investors approximately 3.05% in annual dividends.
Duke Energy Corporation
Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) is one of the largest electric power companies in the U.S. and is known for its stable revenue and consistent dividends. DUK generates around 3.62% in annual dividend yield.
Apple
Technology giant Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has a modest dividend yield but a strong growth potential, and that&#8217;s why both growth and income-focused investors are attracted to this stock. APPL pays investors around 0.47% in dividends per year.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Mastercard
Electronic payments company Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) benefits from the ongoing shift toward cashless transactions. This, and the growth potential it offers makes MA a go-to stock for many investors. The company generates around 0.56% in annual dividends.
Verizon
Telecom Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) provides wireless and wireline services. With a dividend yield of approximately 6.25% annually, VZ has a stable cash flow, making it a favorite among individual stock investors.
Altria Group
Tobacco giant Altria Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is mainly known for the Marlboro brand. MO offers a high dividend yield of 7.21% per year, appealing to those seeking higher passive income.
Global X SuperDividend ETF
Tracking the performance of the Indxx SuperDividend U.S. Low Volatility Index, Global X SuperDividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIV#NYSE">DIV</a>) focuses on high dividend yields and is known to retain low volatility. DIV generates around 11.37% in dividend yield per year.
Invesco Preferred ETF
Invesco Preferred ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGX#NYSE">PGX</a>) invests mainly in preferred stocks, which are hybrid securities offering features of both stocks and bonds.​ Paying investors around 5.85% in annual dividends, PGX is a favorite for those who seek higher income.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

AAPL

ABBV

From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 22% bullish and 77%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $659,000, and 2 are calls, for a total amount of $110,995.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $130.0 for Abbott Laboratories over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abbott Laboratories's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abbott Laboratories's significant trades, within a strike price range of $115.0 to $130.0, over the past month.
<h3>Abbott Laboratories Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742934628_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.05</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$125.00</td>
<td>$357.0K</td>
<td>2.6K</td>
<td align="right">698</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.55</td>
<td>$8.5</td>
<td>$8.55</td>
<td>$125.00</td>
<td>$74.3K</td>
<td>2.6K</td>
<td align="right">47</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.61</td>
<td>$2.6</td>
<td>$2.61</td>
<td>$125.00</td>
<td>$72.5K</td>
<td>4.7K</td>
<td align="right">97</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.7</td>
<td>$8.6</td>
<td>$8.63</td>
<td>$125.00</td>
<td>$61.1K</td>
<td>2.6K</td>
<td align="right">258</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.29</td>
<td>$129.00</td>
<td>$56.6K</td>
<td>21</td>
<td align="right">518</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Abbott Laboratories</h3>
<ul>
<li>With a volume of 6,176,592, the price of ABT is down -1.27% at $125.6. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>Expert Opinions on Abbott Laboratories</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $154.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $160. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Abbott Laboratories with a target price of $154. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Abbott Laboratories with a target price of $150. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Abbott Laboratories options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Behind the Scenes of Abbott Laboratories's Latest Options Trends

Abbott Laboratories Announces That The FDA Has Approved An Investigational Device Exemption  For Its Coronary Intravascular Lithotrips  System To Evaluate The Treatment Of Severe Calcification In Coronary Arteries Prior To Stenting

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.93 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Abbott Laboratories?

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 60%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $305,520, and 8 are calls, for a total amount of $280,024.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $135.0 for Abbott Laboratories over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Abbott Laboratories's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Abbott Laboratories's substantial trades, within a strike price spectrum from $75.0 to $135.0 over the preceding 30 days.
<h3>Abbott Laboratories Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742313635_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$13.9</td>
<td>$13.4</td>
<td>$13.4</td>
<td>$130.00</td>
<td>$245.2K</td>
<td align="right">8</td>
<td align="right">228</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.25</td>
<td>$13.4</td>
<td>$13.4</td>
<td>$130.00</td>
<td>$60.3K</td>
<td align="right">8</td>
<td align="right">45</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$135.00</td>
<td>$47.4K</td>
<td align="right">456</td>
<td align="right">325</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.9</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$135.00</td>
<td>$39.2K</td>
<td align="right">507</td>
<td align="right">174</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$135.00</td>
<td>$36.9K</td>
<td align="right">507</td>
<td align="right">352</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Abbott Laboratories</h3>
<ul>
<li>Trading volume stands at 2,698,821, with ABT's price down by -1.06%, positioned at $126.28.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Abbott Laboratories</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $154.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $154. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Abbott Laboratories, maintaining a target price of $160. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Decoding Abbott Laboratories's Options Activity: What's the Big Picture?

B of A Securities analyst Travis Steed maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $133 to $150.

Price Target

B of A Securities Maintains Buy on Abbott Laboratories, Raises Price Target to $150

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories.
Looking at options history for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $101,085 and 8, calls, for a total amount of $453,044.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $150.0 for Abbott Laboratories over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abbott Laboratories's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abbott Laboratories's significant trades, within a strike price range of $120.0 to $150.0, over the past month.
<h3>Abbott Laboratories Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741625142_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.0</td>
<td>$8.85</td>
<td>$9.0</td>
<td>$140.00</td>
<td>$97.2K</td>
<td>400</td>
<td align="right">110</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.0</td>
<td>$12.45</td>
<td>$140.00</td>
<td>$73.4K</td>
<td>2.0K</td>
<td align="right">10</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$10.75</td>
<td>$10.6</td>
<td>$10.75</td>
<td>$135.00</td>
<td>$64.4K</td>
<td>505</td>
<td align="right">125</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$5.05</td>
<td>$4.9</td>
<td>$5.05</td>
<td>$120.00</td>
<td>$57.0K</td>
<td>239</td>
<td align="right">113</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$12.85</td>
<td>$12.15</td>
<td>$12.45</td>
<td>$140.00</td>
<td>$56.0K</td>
<td>2.0K</td>
<td align="right">450</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
In light of the recent options history for Abbott Laboratories, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Abbott Laboratories Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,067,951, the ABT's price is up by 1.15%, now at $138.72. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>What The Experts Say On Abbott Laboratories</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $157.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Abbott Laboratories with a target price of $154. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Abbott Laboratories, targeting a price of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment

March 6, 2025 records indicate that Senator Shelley M Capito filed a sale of Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), valued between $5,005 and $75,000. According to the March filing, the transaction occurred on March 6, 2025.
Currently, Comcast shares are trading up 1.12% at $36.67.
<h3>What Senator Has Been Trading Recently</h3>
Over the past three years, Shelley M Capito executed 117 trades totaling over $201 thousand. The largest of these trades were in Intel and Duke Energy stock. Some of the key transactions the Sen. has executed recently include: 
<ul>
<li>Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): $1,001 - $15,000 Sale</li>
<li>Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>): $1,001 - $15,000 Purchase</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here is a list of Shelley M Capito's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta Platforms Inc</td>
<td></td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-02-25</td>
</tr>
<tr>
<td>Comcast</td>
<td>CMCSA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-02-24</td>
</tr>
<tr>
<td>Accenture</td>
<td>ACN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-02-24</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-02-24</td>
</tr>
<tr>
<td>Apple</td>
<td>AAPL</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-02-05</td>
</tr>
</tbody>
</table>
To stay updated on Shelley M Capito's trades and other congressional trades, try our <a href="https://www.benzinga.com/gov-trades/members/shelley-m-capito">government trades tool</a> for live updates!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Politics

CMCSA

Recent Report Shows That Sen. Shelley M Capito Sold Up to $75K Worth of Comcast Stock

March 6, 2025 records indicate that Representative Jared Moskowitz filed a sale of West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), valued between $1,001 and $15,000. According to the March filing, the transaction occurred on March 6, 2025.
Currently, West Pharmaceutical Servs shares are trading down 0.0% at $232.76.
<h3>Representative's Recent Trading Activity</h3>
Over the previous three years, Jared Moskowitz conducted 293 trades, totaling more than $602 thousand. The largest of these were in Raymond James Finl and Seacoast Banking stock. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Jared Moskowitz's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>AbbVie</td>
<td>ABBV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-01-15</td>
</tr>
<tr>
<td>AbbVie</td>
<td>ABBV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-01-15</td>
</tr>
</tbody>
</table>
Stay informed on Jared Moskowitz's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/jared-moskowitz">government trades tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stock

High-rolling investors have positioned themselves bullish on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ABT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Abbott Laboratories. This is not a typical pattern.
The sentiment among these major traders is split, with 72% bullish and 9% bearish. Among all the options we identified, there was one put, amounting to $41,820, and 10 calls, totaling $728,484.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $115.0 to $145.0 for Abbott Laboratories over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Abbott Laboratories's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Abbott Laboratories's substantial trades, within a strike price spectrum from $115.0 to $145.0 over the preceding 30 days.
<h3>Abbott Laboratories 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741284072_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.25</td>
<td>$21.95</td>
<td>$22.25</td>
<td>$115.00</td>
<td>$277.9K</td>
<td>1.2K</td>
<td align="right">127</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$3.65</td>
<td>$3.05</td>
<td>$3.65</td>
<td>$132.00</td>
<td>$91.2K</td>
<td>202</td>
<td align="right">1</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$17.55</td>
<td>$16.45</td>
<td>$16.95</td>
<td>$120.00</td>
<td>$83.0K</td>
<td>533</td>
<td align="right">49</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.8</td>
<td>$5.75</td>
<td>$5.8</td>
<td>$145.00</td>
<td>$73.6K</td>
<td>321</td>
<td align="right">128</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.85</td>
<td>$6.7</td>
<td>$6.85</td>
<td>$135.00</td>
<td>$45.2K</td>
<td>1.1K</td>
<td align="right">235</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Abbott Laboratories's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,532,529, the price of ABT is down by -2.37%, reaching $134.44.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Abbott Laboratories</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $157.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Abbott Laboratories, which currently sits at a price target of $160. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Abbott Laboratories, targeting a price of $154. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

During the last three months, 8 analysts shared their evaluations of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, accompanied by a high estimate of $160.00 and a low estimate of $135.00. This current average reflects an increase of 5.45% from the previous average price target of $137.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1741114836_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Abbott Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$154.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$158.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Abbott Laboratories's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>All You Need to Know About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Abbott Laboratories: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.16%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Abbott Laboratories's net margin excels beyond industry benchmarks, reaching 84.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Abbott Laboratories's ROE excels beyond industry benchmarks, reaching 21.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA excels beyond industry benchmarks, reaching 11.85%. This signifies efficient management of assets and strong financial health.
Debt Management: Abbott Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.32.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Abbott Laboratories Stands With Analysts

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $160.

Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $160

Goldman Sachs analyst David Roman maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $138 to $154.

Goldman Sachs Maintains Buy on Abbott Laboratories, Raises Price Target to $154

<ul>
<li>Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3&#x2122; LVAD patients</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cadrenal.com%2F&amp;esheet=54218519&amp;newsitemid=20250304792377&amp;lan=en-US&amp;anchor=Cadrenal+Therapeutics&amp;index=1&amp;md5=849cf8be59121165ab208f7f5b1ad1c8">Cadrenal Therapeutics</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) to support Cadrenal's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3&#x2122; trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3&#x2122; expertise.

CVKD

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott In Support Of Pivotal Study Of Tecarfarin In Patients With HeartMate 3 LVAD

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 21.7% since its last report. The company recently reported that it has 22.31 million shares sold short, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740762042_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.10%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

On Thursday, Dexcom, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fourth-quarter&nbsp;revenue rose 8% year-over-year to&nbsp;$1.114 billion,&nbsp;beating the analyst consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of&nbsp;$1.104 billion</a>.
U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and <a target="_blank" href="https://www.benzinga.com/25/02/43728537/dexcom-tops-sales-forecasts-as-international-growth-soars-19" rel="noreferrer noopener">19% on an organic basis</a>.
Outlook: Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> adjusted operating margin of 21%</a>.
In December, Abbott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products.
The agreement <a target="_blank" href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" rel="noreferrer noopener">will</a> dismiss all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. No financial payments are associated with the settlement from Abbott or Dexcom.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Analyst Reactions: William Blair writes that DME's market share remained steady in Q4, and productivity has improved as planned, following a 40% commercial team expansion last year.
The analyst says the management expects further gains in productivity and another record year for new patient additions in 2025.&nbsp;&nbsp;
While the benefits of these improvements will take several quarters to materialize, especially as 2024 execution challenges fade in the second half, analyst Margaret Kaczor Andrew sees multiple growth drivers that could boost performance in 2025 and sustain revenue and earnings growth in the long term.
Andrew said that DexCom's challenges in 2024 may be temporary. She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups.
However, the analyst points out that DexCom's growth depends on adding new patients, particularly those with early-stage diabetes, with limited clinical data and reimbursement support.
Competition from major players like Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) could also impact DexCom's expansion by capturing a share of new or existing patients in the continuous glucose monitoring market.
Morgan Stanley analyst Patrick Wood maintains DexCom with an Equal-Weight rating and raises the price <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">target from $75 to $82</a>.
Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and raises the price target from $99 to $103.
Price Action: DXCM stock is up 6.22% at $89.32 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a></li>
</ul>

Guidance

DXCM

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

February 11, 2025 records indicate that Representative Emily Randall filed a sale of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), valued between $11,011 and $165,000. According to the February filing, the transaction occurred on February 11, 2025.
Currently, Abbott Laboratories shares are trading down 0.85% at $130.32.
Want to keep up with Emily Randall and other congressional members' stock activities? Check out our <a href="https://www.benzinga.com/gov-trades/members/emily-randall">government trades tool</a> for real-time updates!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 14.97 million shares sold short, which is 0.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739280759_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 3.78%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Abbott Laboratories's Recent Short Interest

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.00</td>
<td>$168.9K</td>
<td>10.7K</td>
<td>17.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$93.00</td>
<td>$49.9K</td>
<td>25</td>
<td>604</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$130.00</td>
<td>$42.9K</td>
<td>6.5K</td>
<td>520</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$53.5K</td>
<td>1.9K</td>
<td>112</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$102.8K</td>
<td>436</td>
<td>56</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$45.0K</td>
<td>124</td>
<td>47</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$650.00</td>
<td>$60.4K</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$65.7K</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$540.00</td>
<td>$27.6K</td>
<td>625</td>
<td>21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding LXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 11262 contract(s) at a $1.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $168.9K, with a price of $15.0 per contract. There were 10734 open contracts at this strike prior to today, and today 17155 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on February 21, 2025. This event was a transfer of 316 contract(s) at a $93.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $158.0 per contract. There were 25 open contracts at this strike prior to today, and today 604 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 272 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $158.0 per contract. There were 6570 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 143 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $535.0 per contract. There were 1923 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option trade with neutral sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $102.8K, with a price of $2235.0 per contract. There were 436 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a call option sweep that happens to be bullish, expiring in 143 day(s) on June 20, 2025. This event was a transfer of 47 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $968.0 per contract. There were 124 open contracts at this strike prior to today, and today 47 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on September 19, 2025. Parties traded 30 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $2016.0 per contract. There were 70 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $65.7K, with a price of $2630.0 per contract. There were 6 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on April 17, 2025. This event was a transfer of 10 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $27.6K, with a price of $2760.0 per contract. There were 625 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKRO

LNTH

LXRX

REGN

9 Health Care Stocks With Whale Alerts In Today's Session

Press Releases

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care

Dividends

Abbott Declares 405th Consecutive Quarterly Dividend

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease

Abbott Hosts Conference Call for First-Quarter Earnings

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

B of A Securities

Citigroup

Goldman Sachs

Barclays

RBC Capital

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2025-02-24 at 6.22.23 PM

GCTK

Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial

Screenshot 2024-12-03 at 7.43.04 PM

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

수요일(22일) 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)는 4분기 매출이 전년 동기 대비 7.2% 증가한 109억 7,000만 달러로 <a href="https://www.benzinga.com/25/01/43131874/abbott-q4-sales-fall-short-of-estimates-issues-q1-profit-guidance-lower-than-street-view" target="_blank" rel="noopener">컨센서스인 110억 1,000만</a> 달러에 미치지 못했다고 발표했다.
또한 기본 사업의 유기적 매출 성장률은 8.8%였다. 비교하자면 코로나19 테스트 관련 매출을 제외한 유기적 매출 성장률은 10.1%였다.
스티펠의 애널리스트 릭 와이즈(Rick Wise)는 애보트의 2024년 4분기 실적과 2025년 전망에 대해 긍정적인 전망을 내놓았다. 그는 당뇨병 관리 및 구조적 심장 부문에서 강력한 모멘텀이 있으며, 이는 의료기기 부문의 두 자릿수 성장과 회사 전체의 높은 한 자릿수 성장을 견인할 것으로 예상하고 있다.
애보트 CEO인 로버트 포드(Robert Ford)는 당뇨병 관리 부문의 주요 성장 기회에 대해 설명했다. 여기에는 인슐린을 많이 사용하는 환자들의 연속 혈당 측정기(CGM) 사용 증가, Libre 시스템의 인슐린 펌프 연결성을 통한 시장 점유율 확대, Lingo CGM을 통한 소비자 시장 공략 등이 포함된다.
또한 애보트는 내부 비용 이니셔티브의 성공을 반영하여 150bp의 영업 마진 개선을 달성할 것으로 예상하고 있다. 이를 통해 장기적으로 두 자릿수 퍼센트의 주당순이익 성장을 유지할 수 있을 것으로 예상한다.
릭 와이즈는 애보트의 사업 부문이 보다 독특한 제품을 제공하고 있으며, 코로나19 이후 회복세가 지속됨에 따라 의료 기술 부문에서 강력한 성장세를 보일 것으로 전망했다. 이들은 향후 몇 년 동안 더 나은 실행, 프랜차이즈 전반에 걸친 주요 제품 출시, 현금 창출과 부채 감소에 더욱 집중함으로써 애보트의 매출과 이익이 개선될 것으로 예상한다.
스티펠은 애보트의 목표주가를 기존 130달러에서 135달러로 <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noopener">상향 조정하고 매수 의견을 유지했다.</a>
한편 파이퍼 샌들러는 애보트의 4분기 보고서가 긍정적이었으며, 새해에도 탄탄한 실적을 거둘 것으로 예상했다. 애널리스트인 애덤 매더(Adam Maeder) 주가에 대해 건설적인 시각을 유지하고 있으며, 대형주 의료기술(MedTech) 분야에서 GARP에 노출될 수 있는 가장 좋은 방법은 애보트 주식이라고 생각한다. 파이퍼 샌들러는 133달러 목표주가와 비중확대 의견을 유지했다.
ABT 주가 움직임: 목요일 애보트 래버러토리스 주가는 4.62% 상승한 123.22달러로 마감했다.
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 추가적으로 개선되었음을 보여주었지만, 수요일(22일) 여전히 &#8220;공포&#8221; 영역에 머물렀다.
미국 주식은 수요일에 상승 마감하였으며, S&amp;P 500 지수는 장중에 사상 최고가로 상승했다.
넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)는 화요일에 예상치를 크게 상회한 4분기 재무 실적을 발표했다. 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>)도 예상보다 좋은 2분기 재무 실적을 발표했다. 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)는 4분기 매출이 109억 7천만 달러로 전년 대비 7.2% 증가했지만, 컨센서스인 110억 1천만 달러를 하회했다고 발표했다.
경제지표 측면에서, 미국의 주택담보대출 신청건수는 1월 17일 주간에 전주 대비 0.1% 증가했다.
S&amp;P 500 지수 대부분의 섹터가 부정적인 흐름으로 마감되었고 특히 유틸리티, 부동산, 에너지 섹터가 하락했다. 그러나 정보기술과 통신서비스 섹터는 상승 마감했다.
다우존스 지수는 수요일에 약 131포인트 상승하여 44,156.73포인트로 마감, S&amp;P 500은 0.61% 상승하여 6,086.37포인트로 마감했다. 나스닥 종합지수는 1.28% 상승하여 20,009.34포인트로 마감했다.
투자자들은 오늘 GE 에어로스페이스NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), 아메리칸항공(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), 유니온 퍼시픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 43.3을 기록하고 있고 수요일에 여전히 &#8220;공포&#8221; 영역에 머물렀다. 이전 수치는 41.5였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

S&P 500 사상 최고치 경신, 넷플릭스의 강력한 실적: 투자 심리 개선되었지만 탐욕 지수는 계속 '공포' 영역에

S&amp;P 500이 수요일에 6,100포인트를 잠시 넘기며 새로운 사상 최고치를 기록했다. 이는 강력한 기업 실적과 도널드 트럼프 대통령의 5,000억 달러 규모의 인공지능(AI) 투자 계획인 &#8220;<a href="https://www.benzinga.com/25/01/43139410/softbanks-role-in-500-billion-stargate-ai-venture-seen-as-major-growth-driver-analyst-says">AI 스타게이트</a>&#8220;의 발표로 월가가 긍정적으로 반응한 결과이다.
이 프로젝트는 미국의 AI 인프라를 혁신하는 것을 목표로 하며, 이미 예상보다 강한 4분기 실적과 올해 후반에 연방준비제도(연준)의 금리 인하 기대감이 높아진 시장에 추가적인 활력을 불어넣었다.
대형 기술 주식과 반도체 기업들이 이끌면서 S&amp;P 500 — SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 지수 — 는 최근 7거래일 중 6거래일 동안 상승했다.
수요일 정오까지 S&amp;P 500은 6,100.4포인트에 도달하여 12월 6일에 세운 이전 기록인 6,099포인트를 간신히 넘겼다.
자세한 내용 보기: <a href="https://www.benzinga.com/25/01/43142623/happy-birthday-sp-500-spy-etf-if-you-invested-1000-in-spy-at-launch-heres-how-much-youd-have-today">S&amp;P 500 SPY ETF의 생일을 축하! SPY 출시 시 1,000달러를 투자했다면 현재 얼마나 되었을까?</a>
<h3 class="wp-block-heading">AI 스타게이트: AI 인프라에 대한 게임 체인저 투자</h3>
트럼프는 1월 21일 AI 스타게이트를 발표했다. 이 합작 투자에는 샘 올트먼이 이끄는 오픈AI, 손 마사요시이 지원하는 소프트뱅크 및 오라클(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)이 함께 참여하여 차세대 AI 인프라를 구축하는 프로젝트이다.
이 프로젝트는 향후 4년 동안 최대 5,000억 달러를 투자하여 미국 전역에 대규모 AI 데이터 센터를 구축하는 것을 목표로 하며, 초기 단계에는 1,000억 달러가 투자된다.
트럼프는 이 이니셔티브를 &#8220;미국의 잠재력에 대한 신뢰 선언&#8221;으로 칭하며, AI 기술의 미래를 미국 국경 내에 두는 것의 중요성을 강조했다.
AI 스타게이트는 거의 즉시 10만 개의 일자리를 창출할 것으로 예상되며, 이는 경제 성장에 대한 낙관론을 더욱 강화한다.
<h3 class="wp-block-heading">실적 강세가 시장 낙관론을 자극</h3>
AI에 대한 기대감이 헤드라인을 장식한 가운데, 강력한 기업 실적 시즌이 시장 상승의 기초를 마련했다.
팩트셋(FactSet)에 따르면, 1월 17일 기준으로, 4분기 실적을 발표한 S&amp;P 500 기업 중 81%가 월가의 이익 예상을 초과했으며, 64%가 매출 예상치를 초과한 것으로 나타났다.
이번 주 실적을 발표한 대형 기업들 — 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), 찰스 슈왑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), 프로로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>), 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) 및 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) — 모두 예상을 초과하여 발표되었으며, 이는 투자자들의 미국 기업에 대한 신뢰를 강화했다.
&#8220;S&amp;P 500의 선행 이익률은 2025년 1월 18일 주에 기록적인 13.6%에 달했으며, 이는 1년 전의 12.7%에서 0.9포인트 증가한 수치이다&#8221;라고 베테랑 투자자인 에드 야데니(Ed Yardeni)가 수요일 노트에서 밝혔다.
&#8220;트럼프 행정부가 큰 재정적 역풍에 직면하더라도 기업의 수익성은 계속해서 개선될 것이다.&#8221;
<h2 class="wp-block-heading">기술 대기업들이 시장을 상승</h2>
수요일의 상승은 이른바 &#8220;매그니피센트 7&#8221; 주식들이 중심에 있었으며, Roundhill Magnificent Seven ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>)가 1.53% 상승했다.
마이크로소프트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>)는 4.13% 급등했으며, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 4.43% 상승 마감하여 AI 경쟁에서의 지배력을 강화했다. 반도체 주식들은 AI 관련 인프라 수요 증가에 대한 투자자들의 베팅으로 특히 강한 상승세를 보였다.
소프트뱅크가 소유한 반도체 설계 회사 Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)는 15.93% 급등하며 2024년 2월 이후 가장 큰 단일 일간 상승률을 기록했다.
소프트뱅크의 2024년 연례 보고서에서는 Arm이 &#8220;인공지능 초지능(AI Super Intelligence)을 위한 기초 기술&#8221;을 제공한다고 설명했으며, 이는 AI 스타게이트가 구체화됨에 따라 점점 더 관련성이 높아 보인다.
<h3 class="wp-block-heading">S&amp;P 500 사상 최고가를 이끈 6종목</h3>
수요일에 시장의 급등을 이끈 것은 몇몇 회사들이었다.
엔비디아와 마이크로소프트는 S&amp;P 500의 상승에 각각 53bp(베이시스포인트)를 기여했으며, 넷플릭스, 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) 및 오라클은 함께 18bp를 추가했다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>종목명</th>
<th>가격</th>
<th>S&amp;P 500 내 비중</th>
<th>1일 %변화</th>
<th>S&amp;P 500 기여도</th>
</tr>
</thead>
<tbody>
<tr>
<td>엔비디아</td>
<td>$1,472.46</td>
<td>6.51%</td>
<td>4.55%</td>
<td>+29bp</td>
</tr>
<tr>
<td>마이크로소프트</td>
<td>$445.37</td>
<td>6.27%</td>
<td>3.94%</td>
<td>+24bp</td>
</tr>
<tr>
<td>넷플릭스</td>
<td>$952.64</td>
<td>0.72%</td>
<td>9.54%</td>
<td>+6bp</td>
</tr>
<tr>
<td>아마존닷컴</td>
<td>$233.46</td>
<td>4.10%</td>
<td>1.19%</td>
<td>+5bp</td>
</tr>
<tr>
<td>메타 플랫폼스</td>
<td>$626.13</td>
<td>2.65%</td>
<td>1.57%</td>
<td>+4bp</td>
</tr>
<tr>
<td>오라클</td>
<td>$184.92</td>
<td>0.51%</td>
<td>7.15%</td>
<td>+3bp</td>
</tr>
</tbody>
</table>
</figure>
지금 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/indices/%EB%8F%85%EC%A0%90-sp-500%EC%9D%B4-%ED%8A%B8%EB%9F%BC%ED%94%84%EC%9D%98-%EB%91%90%EB%B2%88%EC%A7%B8-%EC%9E%84%EA%B8%B0-%EB%8F%99%EC%95%88-%EC%B2%AB%EB%B2%88%EC%A7%B8%EC%99%80-%EA%B0%99%EC%9D%80/" target="_blank" rel="noopener">S&amp;P 500이 트럼프의 첫 임기 동안 기록한 큰 상승폭을 두 번째로 반복할 수 있을까요? 독자들이 말하는 이 수익률 범위가 가장 가능성이 높습니다&#8230;</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

S&P 500이 6,100의 최고가를 경신: 강력한 기업 실적, 트럼프의 AI 베팅이 상승을 격려

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 개선된 것으로 나타냈지만, 화요일(21일)에도 여전히 &#8216;공포&#8217; 영역에 머물렀다.
화요일 미국 증시는 도널드 트럼프가 1월 20일 제47대 미국 대통령으로 취임한 이후 투자자들이 국내 친화적인 정책에 베팅하면서 다우존스 지수가 장중 500포인트 이상 상승하는 등 상승세로 마감했다.
3가지 주요 지수 모두 2025년의 첫 주간 상승을 기록했다. 지난주 다우존스 지수는 3.7%, S&amp;P 500 지수는 2.9% 상승했다. 한편, 나스닥 지수는 한 주 동안 2.5% 상승하며 12월 이후 가장 강력한 주간 실적을 기록했다.
DR호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)은 예상보다 양호한 1분기 실적을 발표했다. 3M(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)도 2024년 4분기 호실적을 발표하고 2025년 긍정적 가이던스를 제시했다.
화요일에는 산업, 부동산, 헬스케어 섹터가 상승세를 기록하는 등 S&amp;P 500 지수 대부분의 섹터가 상승세로 마감했다. 그러나 에너지주는 전체 시장 추세를 역행하며 하락세로 마감했다.
화요일 다우존스 지수는 약 538포인트 상승한 44,025.81포인트, S&amp;P 500 지수는 0.88% 상승한 6,049.24포인트, 나스닥 종합지수는 0.64% 상승한 19,756.78포인트로 마감했다.
투자자들은 오늘 애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 화요일 현재 40.8을 기록하며 &#8220;공포&#8221; 영역에 머물렀다. 이전 수치는 37.6이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

트럼프 취임 후 다우 지수 500p 상승: 투자 심리 개선, 탐욕 지수는 여전히 '공포' 영역

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보이고 있는 가운데, 오늘 투자자들의 주목을 받을 만한 주식들은 다음과 같다:
<ul>
<li>애보트 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)는 분기 실적을 개장 전 발표할 예정으로, 월스트리트에서 분기 이익이 주당 1.34달러, 매출이 110억 1천만 달러에 이를 것으로 예상하고 있다. 애보트의 주식은 애프터 마켓에서 0.08% 상승하여 116.88달러에 거래되고 있다.</li>
<li>넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)는 예상보다 강력한 4분기 재무 결과를 발표했다. 넷플릭스는 4분기 동안 유료 가입자가 1,891만 명 증가했다고 보고했으며, 이는 전년 대비 15.9% 증가한 수치이다. 이 회사는 연간 매출이 435억달러에서 445억 달러 사이로 예상된다고 발표했으며, 이는 이전 예상보다 5억 달러 증가한 수치이다. 넷플릭스의 주식은 애프터 마켓에서 14.4% 상승하여 994.80달러에 거래되고 있다.</li>
<li>애널리스트들은 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>)이 분기 이익이 주당 1.86달러, 매출이 215억 4천만 달러에 이를 것으로 예상하고 있으며, 시장 개장 전에 실적을 발표할 예정ㅇ이다. 프록터 앤드 갬블의 주식은 애프터 마켓에서 1% 상승하여 163.38달러에 거래되고 있다.</li>
</ul>
프리마켓 보도를 확인하시려면 <a href="https://www.benzinga.com/premarket/">여기</a>를 클릭하세요.
<ul>
<li>인터랙티브 브로커스 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>)은 예상보다 좋은 4분기 재무 결과를 발표했다. 이 회사는 주당 2.03달러의 분기 이익을 발표했으며, 이는 애널리스트의 컨센서스 추정치인 1.84달러를 초과한 수치이다. 이 회사는 분기 매출이 13억 9천만 달러로, 애널리스트의 컨센서스 추정치인 13억 7천만 달러를 초과했다고 보고했다. 인터랙티브 브로커스의 주식은 애프터 마켓에서 3.5% 상승하여 199.59달러에 거래되고 있다.</li>
<li>애널리스트들은 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)이 분기 이익으로 주당 2.01달러, 매출이 224억 4천만 달러에 이를 것으로 예상하고 있으며, 개장 전 발표할 예정이다. 존슨앤드존슨의 주식은 애프터 마켓에서 0.6% 상승하여 149.00달러에 거래되고 있다.</li>
<li></li>
</ul>
이것도 확인해보세요:
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">짐 크레이머: 이 기술 주식은 매수, 루이지애나-퍼시픽은 &#8216;훌륭한 주식&#8217;으로 평가받음</a></li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

IBKR

수요일 주목해야 할 주식: 애보트, 넷플릭스, P&G, 인터랙티브 브로커스 및 존슨앤드존슨

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.
콜럼버스 데이는 1492년 크리스토퍼 콜럼버스의 북미 착륙을 기념하는 연방 공휴일로, 뉴욕 증권 거래소와 나스닥 주식 시장은 평소와 같이 운영된다. 장외(OTC) 시장도 개방되지만, 채권 시장은 휴장한다. 미국 우편 서비스와 연방 준비 제도도 운영되지 않으며, 많은 은행도 이를 따른다.
일부 주에서는 이 날을 원주민 공동체의 회복력을 기념하는 원주민의 날로 인정하기도 한다.
참고: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299648/bitcoin-ethereum-dogecoin-see-friday-gains-but-trader-warns-59-000-must-hold-no-major-move?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 이더리움, 도지코인이 금요일 상승을 보였지만, 트레이더는 &#8216;59,000달러는 유지되어야 한다&#8217;고 경고했다.</a>
국제적으로는 대부분의 시장에서 거래가 평소와 같이 계속되지만, 토론토 증권 거래소는 캐나다 추수감사절을 기념하여 휴장한다.
투자자들은 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 애벗 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), 대만 반도체 제조(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)와 같은 주요 기업들의 실적 발표가 있는 바쁜 주를 대비해야 한다. 또한, 실업 수당 청구, 소매 판매, 주택 착공 등의 주요 경제 지표 발표가 현재 경제 상태에 대한 통찰력을 제공할 것이다.
가격 동향: 작성 시점에 월요일 프리마켓에서 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 약 0.22% 상승하여 약간 높은 가격으로 거래되었으며, Invesco QQQ Trust, Series 1(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.32% 상승했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41288392/justin-biebers-2024-crypto-returns-discover-how-much-the-pop-icon-made-on-his-ethereum-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">저스틴 비버의 2024년 크립토 수익 – 팝 아이콘이 그의 이더리움 투자로 얼마나 벌었는지 알아보세요!</a></li>
</ul>
이미지 출처: Shutterstock
이 콘텐츠는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>가 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

콜럼버스 데이: 오늘 주식시장이 열리나요?

목요일 아침 (동부 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li>월스트리트는 D.R. 호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)이 개장 전 매출 97억 7천만 달러, 주당 3.77달러의 분기 이익을 보고할 예정이다. <a href="https://pro.benzinga.com/dashboard">벤징가 프로</a>의 데이터에 따르면 D.R. 호튼의 주식은 시간외 거래에서 0.3% 상승한 158.00달러를 기록했다.</li>
<li>목요일, 노바티스 AG(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)는 2분기에 대해 긍정적인 실적을 발표했다. 이 회사는 분기별 조정 이익을 주당 1.97달러로 보고했는데, 이는 시장 추정치인 주당 1.89달러를 뛰어넘는 수치이다. 매출은 125억 1,200만 달러로 예상치 123억 7,500만 달러를 넘어섰다. 노바티스의 주가는 시간외 거래에서 0.04% 상승한 111.85달러를 기록했다.</li>
<li>분석가들은 애보트 래버러토리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)가 분기별 이익을 주당 1.10달러, 매출 103억 7천만 달러로 기록할 것으로 예상한다. 이 회사는 개장 전에 실적을 발표할 예정이다. 애보트의 주가는 시간외 거래에서 0.1% 상승한 104.83달러를 기록했다.</li>
</ul>
<a href="https://www.benzinga.com/premarket" target="_blank" rel="noopener">여기에서 프리마켓 커버리지</a>를 확인하세요.
<ul>
<li>대만 반도체 제조 (TSMC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)는 예상보다 나은 2분기 실적을 발표했다. TSMC의 주가는 시간외 거래에서 2.4% 상승한 175.33달러를 기록했다.</li>
<li>분석가들은 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)가 시장 마감 후 95억 3천만 달러의 매출과 분기 이익을 주당 4.74달러로 기록할 것으로 예상한다. 넷플릭스의 주가는 시간외 거래에서 0.4% 상승한 649.85달러를 기록했다.</li>
</ul>
Photo courtesy: DR Horton
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일 주목해야 주식: D.R. 호튼, 노바티스, 넷플릭스 그리고  2종목

뉴욕 증권 거래소(NYSE)의 여러 주식들은 <a href="https://www.benzinga.com/topic/nyse">기술적 문제</a>로 인해 월요일 동부 표준시 오전 9시 40분 이후 갑자기 거래가 중단되었다.
이번 예상치 못한 거래 중단은 일반적으로 단일 주식의 과도한 변동성을 억제하는 데 사용되는 &#8220;상향 한도(Limit Up)/하향 한도(Limit Down)&#8221; 코드로 분류된 기술적 문제로 인해 촉발되었다.
NYSE는 보고된 기술적 문제를 조사 중이라고 밝혔다. NYSE 소유주인 인터콘티넨탈 익스체인지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>)는 &#8220;추가 정보가 최대한 빨리 나올 것&#8221;이라고 밝혔다.
월요일에 급작스러운 거래 일시 중단을 당한 대기업들 중 일부는 동부 시간 오전 9시 50분 52초에 버크셔 해서웨이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)와 9시 44분 58초에 치폴레 멕시칸 그릴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)이 포함됐다.
치폴레의 주가는 3,097달러에서 1,047달러로 66%의 갑작스럽고 극적인 하락을 경험했다. 해당 주식은 오전 10시 21분부터 거래를 재개했다.
오전 9시 49분, 워런 버핏이 소유한 버크셔 해서웨이의 주식은 훨씬 더 심각한 하락에 직면했다. 주가는 622,375달러에서 185.10달러로 99.7%라는 엄청난 폭락으로 거의 소멸될 뻔했다.
월요일의 NYSE 기술적 오작동은 미국 증권 거래소가 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39039375/t-1-settlement-era-on-trading-begins-what-you-need-to-know">1일 결제 기간</a>으로 전환된 지 불과 일주일 만에 발생했다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-368052" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03101722/image-4-1024x500.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03101722/image-4-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03101722/image-4-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03101722/image-4-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03101722/image-4-1536x750.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03101722/image-4.png 1920w" alt="" width="1024" height="500" /></figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-368067" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03102012/image-5-1024x500.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03102012/image-5-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03102012/image-5-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03102012/image-5-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03102012/image-5-1536x750.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/03102012/image-5.png 1920w" alt="" width="1024" height="500" /></figure>
<h3 class="wp-block-heading">다른 영향을 받은 주식들</h3>
월요일 뉴욕 증권거래소에서 일어난 급작스럽게 발생한 기술적 오류로 인해 영향을 받은 다른 주식들은 다음과 같다.
<ul>
<li>애벗 래버러토리스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</li>
<li>배릭 골드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>)</li>
<li>프랑코 네바다 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>)</li>
<li>에섹스 프로퍼티 트러스트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>)</li>
<li>누스케일 파워 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)</li>
<li>데스티니 테크 100 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NYSE">DXYZ</a>)</li>
<li>알트 디스럽티브 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADRT#NYSE">ADRT</a>)</li>
<li>누보 몽드 그래파이트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMG#NYSE">NMG</a>)</li>
<li>보우헤드 스페셜티 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOW#NYSE">BOW</a>)</li>
<li>방코 산탄데르-칠레 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSAC#NYSE">BSAC</a>)</li>
<li>로지스틱 프로퍼티 오브 더 아메리카스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>)</li>
<li>엑스페리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>)</li>
<li>ICL 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>)</li>
<li>텔레포니카 S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEF#NYSE">TEF</a>)</li>
<li>트리니티 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>)</li>
</ul>
이 기술적인 문제는 다음 NYSE-Arca 상장 상장지수펀드(ETF)의 거래에도 영향을 미쳤다.
<ul>
<li>Direxion Daily Aerospace &amp; Defense Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFEN#NYSE">DFEN</a>)</li>
<li>MAX S&amp;P 500 4x Leveraged ETN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPRO#NYSE">UPRO</a>)</li>
<li>JPMorgan Core Plus Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCPB#NYSE">JCPB</a>)</li>
<li>Global X MSCI Argentina ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARGT#NYSE">ARGT</a>)</li>
<li>Nationwide Nasdaq-100 Risk-Managed Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUSI#NYSE">NUSI</a>)</li>
<li>SPDR S&amp;P Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XSD#NYSE">XSD</a>)</li>
</ul>
또한 읽기: <a href="https://www.benzinga.com/news/24/06/39136240/koss-corp-tupperware-blackberry-shares-are-moving-monday-whats-going-on">코스, 타파웨어, 블랙베리 주식의 움직임: 무슨 일이?</a>
사진은 셔터스톡(Shutterstock)을 통해 제공됐습니다.

ADRT

ARGT

BSAC

DFEN

DXYZ

GOLD

JCPB

NUSI

UPRO

XPER

버크셔 해서웨이, 치폴레 등 뉴욕 증권 거래소 기술적 문제로 일시 거래 중단 발생

수요일 오전 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 애벗 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)가 개장 전에 98억 8천만 달러의 매출과 주당 95센트의 분기 수익을 보고할 것으로 예상하고 있다. 애벗 주식은 시간 외 거래에서 1% 상승한 110.30달러를 기록했다.
인트라-셀룰러 테라피즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 5억 달러 규모의 보통주 공모 제안을 공개했다. 인트라-셀룰러 테라피즈의 주가는 시간외 거래에서 1.3% 하락한 78.80달러를 기록했다.
분석가들은 U.S. 뱅코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>)의 67억 2천만 달러의 매출과 주당 88센트의 분기 이익을 기록할 것으로 예상하고 있다. 회사는 시장 개장 전에 수익을 발표할 예정이다. U.S. 뱅코프의 주가는 시간외 거래에서 0.6% 하락한 40.75달러를 기록했다.
여기에서 <a href="https://www.benzinga.com/premarket" target="_blank" rel="noopener">개장 전 시황</a>을 확인하세요. 
<div class="sc-bdZQJD kfHPIH all-devices">
<div class="ad-container">
<div class="sc-iLWhZk iosiT">
<div class="adunitContainer"></div>
</div>
</div>
</div>
온트랙(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>)은 예상보다 저조한 4분기 재무 결과를 보고했다. 회사는 주당 21센트의 손실에 대한 시장 기대와 비교하여 주당 27센트의 조정 손실을 기록했습니다. 회사의 분기별 매출은 353만 9천 달러로 추정치인 403만 7천 달러를 놓쳤다. 온트랙 주가는 시간외 거래에서 14.2% 하락한 0.3949달러를 기록했다.
분석가들은 트래블러스 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)가 개장 전에 105억 1천만 달러의 분기 매출과 주당 4.90달러 이익을 기록할 것으로 예상했다. 트래블러스의 주식은 시간외 거래에서 0.8% 상승한 224.98달러를 기록했다.
확인해 보세요: <a href="https://www.benzinga.com/news/24/04/38268727/top-4-tech-stocks-you-may-want-to-dump-in-april" target="_blank" rel="noopener">4월에 투매하고 싶은 상위 4개 기술주</a>

Penny Stocks

ITCI

OTRK

애벗 래버러토리스, U.S. 뱅코프 및 수요일에 주목해야 할 3가지 주식

CNN 머니(Money)의 공포와 탐욕 지수는 화요일에도 &#8216;공포&#8217; 영역에 머물면서 전반적인 시장 심리가 하락한 모습을 보였다.
미국 증시는 지정학적 우려가 커지면서 화요일 혼조세로 마감했다. 한편 다우존스 지수는 6회 연속 하락을 기록했다.
경제 지표를 보면, 3월 미국의 산업 생산은 전월 대비 0.4% 증가했으며, 전월에는 수정된 0.4% 증가를 기록했다. 3월 미국 건축 허가는 연율 145만 8000건으로 4.3% 감소했고, 미국의 주택 착공 건수는 전월 대비 14.7% 감소한 연율 132.1만건을 기록했다.
뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)는 1분기에 예상보다 더 높은 실적을 발표했다. 모건 스탠리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)도 예상보다 더 강한 분기별 재무 결과를 발표했다.
S&amp;P 500의 대부분 섹터는 화요일에 유틸리티, 부동산, 에너지 주식이 가장 큰 손실을 기록하면서 하락 마감했다. 그러나 정보 기술 및 필수 소비재 주식은 전반적인 시장 추세를 거스르며 세션을 높게 마감했다.
다우존스 지수는 화요일 64 포인트 이상 상승하여 37,798.97에 마감했다. S&amp;P 500 지수는 0.21% 하락한 5,051.41에, 나스닥 종합지수 0.12% 하락한 15,865.25에 마감했다.
오늘 트래블러스 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>), U.S. 뱅코프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) 및 애벗 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)의 실적 결과 발표를 기다리고 있다.
화요일 현재 지수는 37.6으로 이전 수치인 39.7에 비해 좀 더 &#8216;공포&#8217; 영역으로 이동했다.
 CNN 비즈니스의 공포와 탐욕 지수란?
공포와 탐욕 지수(Fear &amp; Greed Index)는 현재 시장 심리를 측정하는 지표입니다. 이는 두려움이 높을수록 주가에 압력을 가하는 반면, 탐욕이 높을수록 반대 효과가 나타난다는 전제에 기초한다. 지수는 7개의 동일 가중치 지표를 기반으로 계산된다. 지수 범위는 0에서 100까지이며, 0은 최대 공포를 나타내고 100은 최대 탐욕을 나타낸다.
다음 기사

Comments

Abbott Laboratories

뉴스

에 대한 최신 뉴스 Abbott Laboratories (NYSE:ABT) 주식

금요일, 1월 24, 2025

목요일, 1월 23, 2025

수요일, 1월 22, 2025

월요일, 10월 14, 2024

목요일, 7월 18, 2024

화요일, 6월 04, 2024

수요일, 4월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌